Abstract
In this study we assessed the inyivo antitumor activity of combined docetaxel (DOCE) and doxorubicin (DXR) treatment using 2 human breast carcinoma cell xenografts (R-27 and MX-1) in the nude mouse model. The transplanted tumors were allowed to reach exponential growth, whereupon 10 or 40 mg DOCE per kg alone (ip), 8 mg DXR per kg alone (iv), or 10 mg/kg DOCE (ip) and 8 mg/kg of DXR (iv), in the sequence of DOCE followed by DXR, were administered. The in vivo antitumor activity of combined DOCE and DXR was synergistic against R-27 and additive against MX-1. P-gfycoprotein (P-gp) was detected immunohistochemically, and was highly expressed in R-27, but not in MX-1. In conclusion, DOCE may increase the antitumor activity of DXR against P-gp-positive breast cancer xenografts, such that the DOCE and DXR combination may be a useful treatment in clinical breast cancer.
| Original language | English |
|---|---|
| Pages (from-to) | 23-28 |
| Number of pages | 6 |
| Journal | In Vivo |
| Volume | 17 |
| Issue number | 1 |
| Publication status | Published - 2003 |
Keywords
- Breast cancer
- Combination therapy
- Docetaxel
- Doxorubicin
- In vivo
- P-glycoprotein
- Synergism
ASJC Scopus subject areas
- Biochemistry, Genetics and Molecular Biology(all)
- Pharmacology
